FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
Adam C. Fisher, PhD
Advertisement
Adam C. Fisher, Phd, is Director of Science Staff, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA.
Articles by Adam C. Fisher, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5